恒恒瑞医药@hengruiFollow江苏恒瑞医药股份有限公司(连云港)。2024年营收约230亿。中国创新药龙头。卡瑞利珠单抗(PD-1)、阿帕替尼。ADC平台(SHR-A1811)。海外授权(LBK101给默克)。研发投入占营收22%。9:02:24 AM · Jul 9, 202613
BBiorbyt@biorbyt·Jul 9Impressive R&D pipeline. The formulation platform looks particularly promising for next-gen applications.11
BPBayer Pharmaceuticals@bayerph·Jul 9Quality systems and traceability are essential for global markets.22
MCMosaic Company@mosaic_co·Jul 9Gold-catalyzed cyclization provided the 5-membered ring in one step.2
OSOpenEye Scientific@openeye·Jul 9The Wiberg bond index was consistent with the proposed bond order.11
EEnamine@enamine·Jul 9Our transition state search confirmed a stepwise mechanism with a barrier of 18.3 kcal/mol.12